Contents. Contents (13) 1 Production (23)
|
|
- Alexandrina Lee
- 6 years ago
- Views:
Transcription
1 1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing (31) 1.B.1.1 Clothing material (34) 1.B.1.2 Design of the clothing (35) 1.B.1.3 Preparation/Cleaning (39) 1.B.1.4 Gowning procedure (40) 1.B.2 Code of Conduct (41) 1.B.2.1 Personal hygiene (41) 1.B.2.2 General requirements (42) 1.B.2.3 Special requirements for clean rooms (42) 1.B.2.4 Policies to be established (43) 1.B.3 Hand disinfection (44) 1.B.4 Health requirements (45) 1.B.5 Training (46) 1.C Production hygiene (47) 1.C.1 Sources of contamination (50) 1.C.1.1 Premises and facilities (50) 1.C.1.2 Starting materials (52) 1.C.1.3 Packaging materials (52) 1.C.1.4 Cleansing agents, disinfectants and aids (53) 1.C.1.5 Equipment and utensils (54) 1.C.1.6 Process gases (55) 1.C.1.7 Ambient air (55) 1.C.1.8 Processes (56) 1.C.2 Cleaning (56) 1.C.2.1 Cleaning procedure for equipment (57) 1.C.2.2 Cleaning procedure for rooms (57) 1.C.3 Disinfection (58) 1.C.3.1 General procedure (58) 1.D Sanitation programme (61) 1.D.1 Organisation of room cleaning (61) 1.D.1.1 Hygienic areas (61) (13)
2 1.D.1.2 General room cleaning (61) 1.D.1.3 Cleansing agents and disinfectants (62) 1.D.1.4 Cleaning process and aids (64) 1.D.2 Documentation (65) 1.E Environmental monitoring (67) 1.E.1 General (67) 1.E.2 Sampling plan (69) 1.E.3 Establishment of limits and frequencies (70) 1.E.3.1 European requirements (70) 1.E.3.2 US requirements (73) 1.E.3.3 ISO standards (74) 1.E.4 Methods (75) 1.E.4.1 Direct contact test (75) 1.E.4.2 Measurement of airborne microbes (75) 1.E.5 Investigation areas (77) 1.E.5.1 Surfaces (77) 1.E.5.2 Air (78) 1.E.5.3 Cleansing agents and disinfectants (80) 1.E.5.4 Personnel (81) 1.E.5.5 Utilities (82) 1.E.6 Evaluation (82) 1.E.6.1 Report (82) 1.E.6.2 Trend analyses (82) 1.E.6.3 Measures when limit is exceeded (83) 1.F GMP in the production process (85) 1.G Weigh-in (89) 1.G.1 Legal requirements (89) 1.G.2 Weigh-in principles (91) 1.G.2.1 Product-specific weigh-in (92) 1.G.2.2 Raw material-specific weigh-in (92) 1.G.2.3 Central/local weigh-in systems (93) 1.G.2.4 Manual weigh-in (93) 1.G.2.5 Automatic weigh-in (94) 1.G.3 Weigh-in procedure (95) 1.G.3.1 Allocation of raw materials (96) 1.G.3.2 Weigh-in (96) 1.G.3.3 Return (98) 1.G.3.4 Allocation for production (98) 1.G.3.5 Cleaning (98) 1.G.4 Documentation (99) 1.H Identification (101) 1.H.1 Handling of labels (101) 1.H.2 Labelling of starting materials (102) (14)
3 1.H.3 Labelling of equipment and containers (103) 1.H.3.1 General (103) 1.H.3.2 Rejection / Quarantine (104) 1.H.3.3 Cleaning status (105) 1.H.4 Labelling of rooms (107) 1.I In-process control (109) 1.I.1 Objectives (110) 1.I.1.1 Quality control (110) 1.I.1.2 Process control (110) 1.I.2 Organisation and responsibilities (111) 1.I.3 Carrying out (112) 1.I.3.1 Scope and kind of tests (112) 1.I.3.2 Location (115) 1.I.3.3 Sampling (115) 1.I.3.4 Testing (116) 1.I.4 Documentation and evaluation of data (116) 1.J Prevention of cross-contamination (119) 1.J.1 Causes of cross-contamination (119) 1.J.1.1 Rooms (120) 1.J.1.2 Equipment (120) 1.J.1.3 Processes (122) 1.J.1.4 Personnel (122) 1.J.2 Measures to prevent cross-contamination (123) 1.J.3 Manufacture of critical products (124) 1.K Deviations (127) 1.K.1 Definition (127) 1.K.2 Procedure (128) 1.K.3 Responsibilities (130) 1.K.4 Measures (130) 1.K.5 Failure investigation report (131) 1.K.6 Evaluation of measures (133) 1.K.7 SOP deviations (example) (135) 1.K.8 Check-list for deviation handling (140) 1.L Reworking (145) 1.L.1 Definitions (145) 1.L.1.1 Rework (145) 1.L.1.2 Reprocessing (145) 1.L.1.3 Recovery (145) 1.L.2 Procedure (146) 1.L.2.1 Reasons for rework / reprocessing (146) 1.L.2.2 Request for rework / reprocessing (146) 1.L.2.3 Risk assessment (146) 1.L.2.4 Responsibilities (147) (15)
4 1.L.2.5 Documentation requirements (147) 1.L.2.6 Regulatory submission requirements (148) 1.L.3 Rework / Reprocessing of rejected products (148) 1.L.4 Rework of returned products (152) 1.L.5 Rework of products that have not been rejected (152) 1.M Warehouse and logistics (155) 1.M.1 Regulatory requirements (155) 1.M.2 Stock management system (156) 1.M.3 Responsibilities (160) 1.M.4 Personnel (160) 1.M.5 Storage areas (161) 1.M.5.1 Size (161) 1.M.5.2 Illumination (161) 1.M.5.3 Incoming goods and dispatch (161) 1.M.5.4 Sampling (162) 1.M.5.5 Quarantine (163) 1.M.5.6 Special storage areas (166) 1.M.6 Storage conditions (167) 1.M.6.1 Temperature and humidity (167) 1.M.6.2 Monitoring (167) 1.M.6.3 Deviation handling (170) 1.M.7 Sanitation and pest control (170) 1.M.8 Material Flow (172) 1.M.8.1 Stock rotation (172) 1.M.8.2 Reconciliation (173) 1.M.8.3 Storage systems (173) 1.M.9 Process Flow (176) 1.M.9.1 Receipt (176) 1.M.9.2 Identification (179) 1.M.9.3 Dispatch and transport (181) 2 Packaging (183) 2.A Packaging material (185) 2.A.1 Responsibilities (186) 2.A.2 (186) 2.A.3 Materials (186) 2.A.4 Protection against counterfeit medicinal products (190) 2.A.5 Packaging material testing (191) 2.A.5.1 Control tests carried out at the supplier (191) 2.A.5.2 Examples (192) 2.A.5.3 Defect evaluation lists (193) 2.A.5.4 Storage (195) 2.A.5.5 Labelling (196) (16)
5 2.B Packaging process (199) 2.B.1 Allocation of packaging material (200) 2.B.2 Line clearance (201) 2.B.3 Labelling (204) 2.B.4 Control functions (204) 2.B.5 Release for production (206) 2.B.6 In-process controls (213) 2.B.6.1 Organisation (213) 2.B.6.2 Function inspections (216) 2.B.6.3 Checking (partially) packed goods (218) 2.B.7 Cleaning primary containers (219) 2.B.8 Labelling (219) 2.B.9 Variable data (220) 2.B.10 Imprints (221) 2.B.11 Reconciliation (222) 2.B.12 Safety features (224) 2.B.13 Completion of a packaging process (224) 2.C Qualification of a packaging line (225) 2.C.1 Master qualification plan (226) 2.C.2 Design qualification (DQ) (232) 2.C.2.1 Design qualification protocol (232) 2.C.2.2 Design qualification report (234) 2.C.3 Installation qualification (IQ) (248) 2.C.3.1 Installation qualification protocol (248) 2.C.3.2 Installation qualification report (253) 2.C.4 Operational qualification (OQ) (258) 2.C.4.1 Operational qualification protocol (258) 2.C.4.2 Operational qualification report (263) 2.C.5 Performance qualification (PQ) (270) 2.C.5.1 Performance qualification protocol (270) 2.C.5.2 Performance qualification report (273) 3 Laboratory and Analytical Controls (277) 3.A Sampling (281) 3.A.1 Requirements (282) 3.A.1.1 Personnel (282) 3.A.1.2 Equipment (282) 3.A.1.3 Containers (283) 3.A.1.4 Premises (283) 3.A.2 Sampling plan (instructions) (283) 3.A.3 Notes for the sampling process (288) 3.A.3.1 Containers and identification labeling (288) 3.A.3.2 Sampling report (288) 3.A.3.3 Reference samples (289) (17)
6 3.B Reagents (291) 3.B.1 Labeling (292) 3.B.2 Usage and stability (292) 3.B.3 Documentation (294) 3.C Standards and reference substances (297) 3.C.1 Definition of different standards and their areas of use (297) 3.C.2 Handling, storage and stability (301) 3.D Qualifying laboratory instruments (305) 3.D.1 Qualification protocols and reports (305) 3.D.1.1 Design qualification (DQ) (306) 3.D.1.2 Installation qualification (IQ) (308) 3.D.1.3 Operational qualification (OQ) (308) 3.D.1.4 Performance qualification (PQ) (308) 3.D.2 System suitability test (SST) (309) 3.E Calibration in the lab (311) 3.E.1 Definitions (311) 3.E.1.1 Persons (311) 3.E.1.2 Instruments (311) 3.E.1.3 Working (312) 3.E.1.4 Laboratory Equipment Inventory List (313) 3.E.2 Calibration instructions and record (314) 3.E.2.1 Test intervals, test points, test instructions (314) 3.E.3 Examples (315) 3.E.3.1 Balance (315) 3.E.3.2 Volume measuring instruments (317) 3.E.3.3 Photometer (319) 3.E.3.4 HPLC system (321) 3.E.4 Decision (330) 3.E.4.1 Requirements, tolerances, specifications (330) 3.E.4.2 Equipment release (330) 3.E.4.3 Out of calibration (330) 3.F Validation of analytical methods (331) 3.F.1 Principles (331) 3.F.2 Definitions of the parameters (333) 3.F.2.1 Precision (333) 3.F.2.2 Accuracy (333) 3.F.2.3 LOD = Limit of Detection (334) 3.F.2.4 LOQ = Limit of Quantitation (334) 3.F.2.5 Selectivity (335) 3.F.2.6 Linearity, Range (335) 3.F.2.7 Robustness (335) 3.F.3 Documentation (336) 3.F.4 Revalidation (336) (18)
7 3.G Stability testing (339) 3.G.1 ICH guidelines for stability tests (340) 3.G.2 Storage and storage conditions (342) 3.G.2.1 Standard storage conditions (342) 3.G.2.2 Packaging (345) 3.G.2.3 Sample quantities (346) 3.G.2.4 Stress test (346) 3.G.2.5 Freeze test (347) 3.G.2.6 Temperature cycling test (348) 3.G.2.7 Special storage conditions for drug products (348) 3.G.2.8 Labeling (350) 3.G.3 Analyses (351) 3.G.3.1 Test parameters (352) 3.G.3.2 Reference samples (353) 3.G.3.3 Consumption test (353) 3.G.3.4 Compatibility test for injection solutions for infusions (353) 3.G.3.5 Analysis of compatibility of rubber stoppers and plastic components (353) 3.G.3.6 Photostability (ICH Q1B) (354) 3.G.3.7 Microbiological analyses (356) 3.G.3.8 Analysis of standing times (357) 3.G.3.9 Analysis of transport conditions (357) 3.G.4 Reduction of the study design (358) 3.G.4.1 Bracketing (359) 3.G.4.2 Matrixing (359) 3.G.5 Stability testing in the marketing phase (362) 3.G.5.1 Follow-up stability testing (FuST) (362) 3.G.5.2 Stability commitment (SC) (363) 3.G.6 Defining the retest period for an active pharmaceutical ingredient and the shelf life for a drug product through evaluation of stability data (ICH Q1E) (375) 3.G.6.1 Data evaluation for the retest period for APIs and shelf life for drug products that are intended for storage at room temperature (375) 3.G.6.2 Data evaluation for retest period for APIs and shelf life for drug products intended for storage in refrigerator (2 8 C) (377) 3.G.6.3 Data evaluation for retest period for APIs and shelf life 3.G.7 for drug products for intended storage in a freezer ( 20 C) (378) Decision tree for data evaluation for retest period or for APIs or drug products (excluding frozen products) (378) 3.G.8 Procedure for statistical analysis (378) 3.G.9 Examples of the statistical evaluation of stability data (380) 3.G.9.1 Data analysis for a single batch (380) 3.G.9.2 Data analysis of one attribute in each batch for several batches of the same product (known as One-Factor, Full-Design Studies) (381) (19)
8 3.G.9.3 Data analysis of all attributes for several batches (Multi-Factor, Full-Design Studies) (382) 3.H Out-of-specification results (383) 3.H.1 Significance (383) 3.H.1.1 The BARR Laboratories case (383) 3.H.1.2 The consequences (385) 3.H.2 Definitions (386) 3.H.3 FDA OOS Guidance (386) 3.H.4 Example for handling of an OOS result (394) 3.H.5 Trend tracking (395) 3.I Raw data documentation (403) 3.I.1 Principles (403) 3.I.2 Single sheet documentation system (405) 3.I.2.1 Cover sheet (405) 3.I.2.2 Data sheet (405) 3.I.2.3 Index sheet (409) 3.J Batch release (411) 3.J.1 Certification by a Qualified Person and release in accordance with EC GMP Guidelines (414) 3.J.1.1 Regulations contained in Directive 2001/83/EC (414) 3.J.1.2 Objectives of appendix 16 (415) 3.J.1.3 Cases of application (416) 3.J.2 Responsibility for issuing the release (418) 3.J.3 Publication of release (419) 3.J.4 Release procedures in practice (420) 3.K Microbiological testing (423) 3.K.1 Total microbial count (424) 3.K.1.1 Determination of the total microbial count (432) 3.K.1.2 Product testing (438) 3.K.1.3 Culture media and culture media checks (440) 3.K.1.4 Incubation (443) 3.K.1.5 Evaluation (443) 3.K.1.6 Validation of the method (445) 3.K.2 Specified microorganisms (446) 3.K.2.1 Detection of specified microorganisms (452) 3.K.2.2 Detection method for the specified microorganisms (454) 3.K.2.3 Evaluation (463) 3.K.2.4 Culture media and culture media tests (464) 3.K.2.5 Suitability test of the method (validation of the methods) (469) 3.K.3 Testing frequencies (470) 3.K.3.1 Preparations (470) 3.K.3.2 Raw materials (471) 3.K.4 Miscellaneous tests (474) (20)
9 3.K.4.1 Monitoring of the hygiene status (474) 3.K.4.2 Aseptic working conditions (477) 4 Documentation (479) 4.A Official requirements (481) 4.A.1 GMP-requirements managed and reviewed according to German pharma business regulations (481) 4.A.2 Requirements of the EU GMP Guideline (484) 4.A.3 Requirements of the US GMP Regulations (488) 4.A.4 Formal requirements (493) 4.A.5 Management and revision documentation (497) 4.B GMP-conforming documentation (501) 4.B.1 Handwritten entries (501) 4.B.2 Archiving (502) 4.B.3 Master-SOP GMP-conforming documentation (503) 4.C Batch documentation (509) 4.C.1 Manufacturing instructions/record (511) 4.C.1.1 Manufacturing instructions (511) 4.C.1.2 Batch processing record (512) 4.C.1.3 Master of manufacturing instructions/batch processing record (514) 4.C.2 Packaging instruction and batch packaging record (534) 4.C.2.1 Packaging instruction (534) 4.C.2.2 Batch packaging record (535) 4.C.3 Electronic batch recording (536) 4.C.3.1 Strategic objectives of an Electronic Batch Recording System (EBRS) (537) 4.C.3.2 GMP aspects (537) 4.C.4 Testing procedures and test protocol (539) 4.C.4.1 Testing procedures (539) 4.C.4.2 Test protocol (541) 4.C.5 Batch record review (544) 4.C.5.1 Regulatory requirements (544) 4.C.5.2 Benefits of an independent batch record review (544) 4.C.5.3 Responsibility and competencies (545) 4.C.5.4 Scope of a batch record review (545) 4.C.5.5 Deviations, changes relevant to marketing authorization, recording errors (546) 4.D Standard operating procedures (SOPs) (549) 4.D.1 Compilation (550) 4.D.1.1 Design and format (552) 4.D.1.2 Identification (554) 4.D.2 Approval and implementation (555) 4.D.3 Training (555) 4.D.4 Usage (556) (21)
10 4.D.5 Review (557) 4.D.6 Changes (557) 4.D.7 Withdrawing an operating procedure (558) 4.D.8 Administration (558) 4.D.8.1 Status identification (558) 4.D.8.2 Distribution (558) 4.D.8.3 Integration (559) 4.D.8.4 Use of computerized systems (559) 4.D.9 Archiving (560) 4.D.10 Example of an SOP Compilation and administration of operating procedures (561) 4.E Site master file (577) 4.E.1 Introduction (577) 4.E.2 Design (577) 4.E.2.1 General information (578) 4.E.2.2 Personnel (579) 4.E.2.3 Premises and equipment (580) 4.E.2.4 Documentation (583) 4.E.2.5 Production (585) 4.E.2.6 Quality control (586) 4.E.2.7 Contract manufacturing and analysis (586) 4.E.2.8 Distribution, complaints and product recall (587) 4.E.2.9 Self-inspection (588) 4.E.2.10 Appendix (589) 4.F Annual product review / Product quality review (591) 4.F.1 Documents required for an annual product review (594) 4.F.2 Annual product review report (596) 4.F.3 Collaboration with a contract manufacturer (598) 4.F.4 Example: annual product review (599) 4.F.5 Master-SOP for the annual product review (604) Index (609) (22)
GMP MANUAL Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel
GMP MANUAL GMP MANUAL 1 Pharmaceutical Quality System (PQS) 1.A Preface 1.B The road to a Pharmaceutical Quality System 1.C Introduction to the PQS 1.C.1 General requirements 1.C (1) 1.C.2 Documentation
More informationGMP MANUAL Contents. 1 Pharmaceutical Quality System (PQS)
GMP MANUAL GMP MANUAL 1 Pharmaceutical Quality System (PQS) 1.A Preface 1.B The road to a Pharmaceutical Quality System 1.C Introduction to the PQS 1.C.1 General requirements 1.C.2 Documentation 1.D Main
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationGMP On Site Series. GMP Essentials
GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history
More informationQuality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
Ref. Ares(2014)968036-28/03/2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, 28 March 2014 EudraLex
More information18.H Questionnaire for preparing GMP-inspections
Questionnaire for preparing -inspections Questionnaire for preparing -inspections Here you will find answers to the following questions: What questions are typically asked during inspections based on current
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND
SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: information about the inspection Name of manufacturer Physical address production departments
More informationGeneral European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT
General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (16) 86 R2 MANAGEMENT OF ENVIRONMENTAL CONDITIONS Full document title and reference Document type Management of Environmental
More informationUNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products
UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF Industry Consultation with Manufacturers and Suppliers of Finished Pharmaceutical Products 29 th 30 th September
More informationHACCP audit checklist
Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal
More informationAnnex 4. Guidance on good manufacturing practices: inspection report. Background
Annex 4 Guidance on good manufacturing practices: inspection report Background The need for revision of the Guidance on good manufacturing practices: inspection report (World Health Organization (WHO)
More informationPAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland
PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec 2004 Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland cca@iol.ie 1 FDA Context 1) FDA 5-Part Strategic Plan Protect &
More informationPIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 010-3 1 October 2008 PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1 General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationAnnex 14 WHO guidelines for drafting a site master file 136
World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix
More informationOn-Site GMP Training GMP COMPLIANCE TECHNICAL
PharmaNet On-Site GMP Training GMP COMPLIANCE TECHNICAL 284 E Lake Mead Pkwy Suite C-278 Henderson, NV 89015 Phone: 702-558-0094 Fax: 702-558-0079 www.gmpseminars.com Key to Level of Program Level A: Program
More informationGUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART I
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 009-11 (Part I) 1 March 2014 GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART I PIC/S March 2014 Reproduction
More informationHISTORY AND MILESTONES
HISTORY AND MILESTONES HISTORY AND MILESTONES DOC S.r.l., Documentation Organization & Consultancy, was established in 1997 by MASCO group C.E.O. Eng. Alberto Borella and Eng. Paolo Curtò who became Managing
More informationRegional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators
Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators Focused on GMP in production of Active Pharmaceutical Ingredients and Oral Solid Dosage Forms Organized
More informationGood Manufacturing Practices Guidance Document
Good Manufacturing Practices Guidance Document Natural Health Products Directorate June 11, 2014 Version 3.0 Table of Contents Foreword... 3 1.0 General overview... 4 1.1 Purpose of the good manufacturing
More informationCOMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION
COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy, Chicago,
More informationRisk classification guide for drug good manufacturing practices observations GUI-0023
Risk classification guide for drug good manufacturing practices observations GUI-0023 January 18, 2017 Risk classification guide for drug good manufacturing practices observations (GUI-0023) Author: Health
More informationQuality Assessment & GMP Similarities & Differences
Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences
More informationTable of Contents. Legal Notices... 61
Notice This manual provides information to excipient manufacturers who intend to participate in the United States Pharmacopeia Ingredient Verification Program for Excipients (USP IVP-E or Program). The
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More informationWhite paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU
White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU Numerous articles are available comparing the current and previous EU Code of GMP Chapter 4: Documentation, but no comparison exists between
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More informationGUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART II
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 009-8 (Part II) 15 January 2009 GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART II Developed by the
More informationAseptic Process Validation
Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1 Overview Guidance Best Practices Common Deficiencies Slide 2 Aseptic
More informationGMP Requirements Based On WHO Guidelines for Ayush Premium Mark
SECTION III VOLUNTARY CERTIFICATION SCHEME FOR AYUSH PRODUCTS Certification Criteria Annex A GMP Requirements Based On WHO Guidelines for Ayush Premium Mark 1. Introduction The increasing use of herbal
More informationGood Manufacturing Practices (GMPs) for Infant Formula
Good Manufacturing Practices (GMPs) for Infant Formula Nutrition Evaluation Division Bureau of Nutritional Sciences Health Products and Food Branch Health Canada 2006 Good Manufacturing Practices (GMPs)
More informationGOVERNMENT NOTICE NO. published on THE TANZANIA FOOD, DRUGS AND COSMETICS ACT (CAP 219) REGULATIONS. (Made under section 122(1)(o))
GOVERNMENT NOTICE NO. published on THE TANZANIA FOOD, DRUGS AND COSMETICS ACT (CAP 219) REGULATIONS (Made under section 122(1)(o)) THE TANZANIA FOOD, DRUGS AND COSMETICS (GOOD MANUFACTURING PRACTICE ENFORCEMENT)
More informationSESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt
Validation Services SESSION 14 Documentation Requirements and Management for Validation 30 March 2017 Frits Vogt fritsvogt@valserv.nl Content Documentation Requirements and Management for Validation I.
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationPROCESS VALIDATION: AN ESSENTIAL PROCESS IN PHARMACEUTICAL INDUSTRY
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Vijayasree et al. SJIF Impact Factor 6.647 Volume 6, Issue 3, 367-874 Review Article ISSN 2278 4357 PROCESS VALIDATION: AN ESSENTIAL PROCESS IN PHARMACEUTICAL
More informationSelf-Evaluation/Audit Checklist for Food Supplement Manufacturers
Self-Evaluation/Audit Checklist for Food Supplement Manufacturers This checklist has been developed by the EHPM quality working group. It combines work carried out by EHPM various national associations
More informationAPIC GUIDE FOR AUDITING REGISTERED STARTING MATERIAL MANUFACTURERS Version February, 2018
APIC GUIDE FOR AUDITING REGISTERED STARTING MATERIAL MANUFACTURERS Version February, 2018 1. PREAMBLE This original version of this guidance document has been compiled by a subdivision of the APIC 3 rd
More informationQuality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines
Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines Longe Sunday Anthony Head- Quality Assurance May & Baker Nigeria Plc. Pharmacentre, Ota, Nigeria eaglesconsult@gmail.com; Slonge@may-
More informationPERFORMANCE QUALIFICATION PROTOCOL HVAC SYSTEM
Page 1 of 24 PERFORMANCE QUALIFICATION PROTOCOL FOR HVAC SYSTEM Signing of this Performance Qualification Protocol indicates agreement with the Validation Master Plan approach of the equipment. Further
More informationAmerican Association for Laboratory Accreditation
Page 1 of 34 This checklist is intended for use in association with A2LA assessments, and is not to be publicly distributed. Use of this document is restricted to A2LA employees, contractors, and applicant
More informationQuestionnaire Layout:
Raw Material Supplier Questionnaire Introduction: This questionnaire has been developed by the EHPM quality working group. It combines work carried out by EHPM various national associations in developing
More informationStandard Answers to FAQs from Customer Questionnaires
Standard Answers to FAQs from Customer Questionnaires 1. Organisation 1.1 Details about the company Company name Hänseler AG Street Industriestrasse 35 Postcode, town 9100 Herisau Country Switzerland Homepage
More informationGMPs: Distribution Centers
SkillsPlus International Inc. The On-Site Series GMPs: Distribution Centers Learn to apply the GMP regulations as they relate to distribution center operations! FDA Past, Present, and Future and opener
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationA.1 Contents file 4 to 5 A.1 (1)
Contents file 4 to 5 Contents file 4 to 5 A Information Contents file 4 to 5 A.2 Index file 4 to 5 A.3 List of Abbreviations A.4 Glossary A.5 Adress-Register A.6 References B Japanese Regulations B.1 MHW
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationGMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP)
GMP Requirements Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP) 2016. ALL RIGHTS RESERVED. Outline GMP Procedures and standards
More informationYour partner in the pharmaceutical industry
English Micronisation- and milling service Micronised by GfM Your API Particle size (µm) Your partner in the pharmaceutical industry The... always that little bit finer. We are a family business in the
More informationCOMMERCIAL PRODUCT STABILITY
COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationLifecycle Product Quality Risk Management
Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,
More informationAnnex 6. Good trade and distribution practices for pharmaceutical starting materials
Annex 6 Good trade and distribution practices for pharmaceutical starting materials Introduction 212 1. Quality management 213 2. Organization and personnel 214 3. Premises 215 4. Procurement, warehousing
More informationTANZANIA FOOD AND DRUGS AUTHORITY
TANZANIA FOOD AND DRUGS AUTHORITY Doc.No.:TFDA/DMC/MCIE/G/013 Rev. 0 GOOD MANUFACTURING PRACTICE GUIDELINES FOR VETERINARY MEDICINAL PRODUCTS (Made under section 51 of the Tanzania Food, Drugs and Cosmetics
More informationThe IFSQN FSSC Implementation Package
This is our premiere package for Food Manufacturers looking to achieve certification to FSSC 22000 for Food Safety Management Systems. Food Safety System Certification (FSSC) 22000 is a Global Food Safety
More informationMEASURE FOR MEASURE: QUALITY METRICS
MEASURE FOR MEASURE: QUALITY METRICS PDA Midwest Chapter Dinner Meeting, Northbrook, IL-9 November 2017 Felicia Ford-Rice, Director, Strategic Compliance 2017 PAREXEL INTERNATIONAL CORP. AGENDA Robust
More informationAt Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.
At Your ServIce Microbiology Services The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. Microbiology Services Optimize your QC lab workflow and ensure regulatory compliance
More informationPreparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014
Preparing Your Aseptic Processing Facility for an FDA Inspection Valerie Welter, Director Quality Bayer HealthCare March 10, 2014 Agenda Regulatory Requirements Establishing your Approach Aseptic Controls
More informationSFHPHARM18 - SQA Unit Code FA2L 04 Prepare aseptic products
Overview This standard covers the preparation of aseptic products including preparing the environment and self. It covers aseptic preparation for both dispensing and manufacturing. Your practice will be
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationAnnex 4. Assessment tool based on the model quality assurance system for procurement agencies: aide memoire for inspection
Annex 4 Assessment tool based on the model quality assurance system for procurement agencies: aide memoire for inspection 1. Introduction 294 2. Purpose 294 3. Scope 294 4. Assessment tool 295 293 WHO
More informationTHE BASIC PRINCIPLES OF HACCP
THE BASIC PRINCIPLES OF HACCP The Meaning of HACCP History of the HACCP System Traditional Inspection HACCP System The Seven Principles of HACCP ١ Meaning of HACCP : Hazard Analysis and Critical Control
More informationGUIDELINES ON GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART 1
GUIDELINES ON GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART 1 National Drug Authority Plot 46-48, Lumumba Avenue, P. O. Box 23096, Kampala, Uganda. Tel: +256-0414 - 255665/347391/2 Fax: +256-0414
More informationQualified Persons in the Pharmaceutical Industry Study Guide
Qualified Persons in the Pharmaceutical Industry Study Guide Guide to the knowledge and practical experience required by Qualified Persons relating to pharmaceutical manufacturing in the UK February 2013
More informationIntroduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES
Introduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES William Garvey and Associates LLC 2016 Introduction About your instructor William (Bill) Garvey Important regulations and events Good Manufacturing
More informationNAFDAC. paths2 GOOD PRACTICES FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES
NAFDAC GOOD PRACTICES FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES 2016 paths2 Partnership for Transforming Health System II...improving pathway to health UKaid from the British people NAFDAC NATIONAL
More informationQ&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document
Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationCALIBRATION AND QUALIFICATION OF EQUIPMENTS IN THE PHARMACEUTICAL INDUSTRY: EMPHASIS ON RADIOPHARMACEUTICALS PRODUCTION
2011 International Nuclear Atlantic Conference - INAC 2011 Belo Horizonte, MG, Brazil, October 24-28, 2011 ASSOCIAÇÃO BRASILEIRA DE ENERGIA NUCLEAR - ABEN ISBN: 978-85-99141-04-5 CALIBRATION AND QUALIFICATION
More informationCUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)
21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software
More informationMicrobiological Consideration for Non-Sterile Pharmaceutical
May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control
More informationGOOD TRADE AND DISTRIBUTION PRACTICES FOR PHARMACEUTICAL STARTING MATERIALS. REVISION
July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 GOOD TRADE AND DISTRIBUTION PRACTICES FOR PHARMACEUTICAL STARTING MATERIALS.
More informationJournal home page: RESEARCH ARTICLE
Journal home page: http://www.journalijiar.com INTERNATIONAL JOURNAL OF INNOVATIVE AND APPLIED RESEARCH RESEARCH ARTICLE QUALITY AUDIT AND GMP INSPECTION OF PHARMACEUTICAL INDUSTRY WITH REFERENCE TO USFDA;
More informationComparison of Guidelines of Indian GMP with WHO GMP
Comparison of Guidelines of Indian GMP with WHO GMP By Dr. Uma Vasireddy, M.Pharm,Ph.D.., Professor and Principal, KIPS,Wgl, INDIA 1 Outline of Presentation Introductory Elements Section wise Comparison
More informationOMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT
OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (13) 113 2R Evaluation and Reporting of Results Core document Full document title and reference Evaluation and Reporting of Results
More informationEnvironmental Monitoring of Aseptic Processing Areas - 1
Environmental Monitoring of Aseptic Processing Areas - 1 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1 Training Course Agenda Overview of Environmental Monitoring
More informationISO 22000:2005 Standard INTERNATIONAL STANDARDS REGISTRATIONS
ISO 22000:2005 Standard Food Safety Management System INTERNATIONAL STANDARDS REGISTRATIONS 3.1 FOOD SAFETY concept that food will not cause harm to the consumer when it is prepared and/or eaten according
More informationThe Cleaning Validation Process
The Cleaning Validation Process The Scope of Cleaning Validation The Cleaning Validation Sequence Prerequisites Cleaning Validation Strategy, Plan, and Policy Sampling Recovery Studies Analytical Method
More informationPharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES
Pharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES DB Schenker Healthcare Conference Europe April 17-18 th 2012 J. BERLO Industrial Pharmacist/Clin. Biol.
More informationFor analytical laboratories. A primer Good laboratory practice and current good manufacturing practice
For analytical laboratories A primer Good laboratory practice and current good manufacturing practice For analytical laboratories A primer Good laboratory practice and current good manufacturing practice
More informationCorrespondence Between ISO 13485:2016 and 21 CFR Part 820 QMS Requirements
Correspondence Between and 21 CFR Part 820 QMS Requirements 10411 Corporate Drive, Suite 102, Pleasant Prairie, WI 53158 262.842.1250 262.842.1240 info@rcainc.com rcainc.com 2 4 Quality Management System
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer Part 1: General information Name of Manufacturer / Iksan Plant Unit number Production Block Physical address Contact person and email
More informationProcess Validation Guidelines. Report highlights 23 rd February 2018
Process Validation Guidelines Report highlights 23 rd February 2018 Process validation is an important element of pharmaceutical quality system An effective system provides assurance of the continued capability
More informationThe validation of biological Active Pharmaceutical
This article presents a procedure for the validation of biological API manufacturing processes. It details each step of the procedure for biological processes applications, and covers the regulatory requirements
More informationProcess validation in medical devices
Process validation in medical devices Fulfil requirements with expert regulatory guidance 1TÜV SÜD Contents INTRODUCTION 4 VALIDATION PLANNING 5 INSTALLATION QUALIFICATION 7 OPERATIONAL QUALIFICATION 9
More informationINDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW
International Journal of Pharmacy Review & Research www.ijprr.com INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW Vishal Sharma* and Nimrata Seth 1 Department of Pharmaceutics, Rayat Institute
More informationRegulatory Expectations, Standards & Guidelines
Regulatory Expectations, Standards & Guidelines Regulatory Requirements Pharmacopeias Good Automated Manufacturing Practice (GAMP) 21 CFR Part 11 and Annex 11 Consequences of Non-Compliance 22 Regulatory
More informationHeating, ventilation, and air system encompasses heating, ventilation, and air conditioning, which is integral component of
REVIEW ARTICLE Demand of pharmaceutical facility functionality: Validation and qualification of HVAC system Anamika Singh, Sapna Malviya, Anil Kharia Department of Quality Assurance of Modern Institute
More informationValidation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness
Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp
More informationAnnex Draft Annex
Anmerkung 1: Dieses Vergleichsdokument wurde nach bestem Wissen und Gewissen erstellt und ist rechtlich nicht bindend. Es gelten die von der EMA veröffentlichten Dokumente in der jeweiligen Form. Anmerkung
More informationQuality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702
Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 11 Status : APPROVED Effective: 09/07/2017 Page 2 of 32 Quality Manual Table of Contents
More informationTECTURA LIFE SCIENCES HIGHLIGHTS
HIGHLIGHTS BATCH AND SERIAL NUMBER MANAGEMENT QUALITY CONTROL VENDOR RATING ELECTRONIC SIGNATURE AND AUDIT TRAIL R&D MODULE MANAGEMENT OF ACTIVE INGREDIENTS SEQUENCE PLANNING MOBILE SCANNER INTEGRATION
More informationReview Validation of aseptic processes for pharmaceuticals
OPEM www.opem.org Oriental Pharmacy and Experimental Medicine 2010 10(4), 231-238 DOI 10.3742/OPEM.2010.10.4.231 Review Validation of aseptic processes for pharmaceuticals Lincy Joseph*, Mathew George
More information